Login / Signup

Dapagliflozin once daily plus exenatide once weekly in obese adults without diabetes: Sustained reductions in body weight, glycaemia and blood pressure over 1 year.

Per LundkvistMaria J PereiraPetros KatsogiannosC David SjöströmEva JohnssonJan W Eriksson
Published in: Diabetes, obesity & metabolism (2017)
Dapagliflozin + exenatide dual therapy produced sustained reductions in body weight, prediabetes and SBP over 52 weeks and was well tolerated in obese adults without diabetes.
Keyphrases